ClinicalTrials.gg
RecruitingNCT06525012HSA RankinUpdated Mar 31, 2025

Observational Study on Mortality and Outcome of Patients Hospitalized for Subarachnoid Hemorrhage of Aneurysmal Origin in Martinique Between 2013 and 2021

An observational study in Subarachnoid Hemorrhage of Aneurysmal Cause, sponsored by University Hospital Center of Martinique. Recruiting at 1 site in Martinique. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-31.

Sponsored by University Hospital Center of Martinique · Observational

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
122
Ages
18 Years and older
Sex
All
01

Study summary

The aim of our study is to analyze mortality and sequelae of subarachnoid hemorrhage of aneurysmal origin in hospitalized patients in Martinique. Predictive factors of poor prognosis will also be analyzed.

Read the detailed description

Subarachnoid hemorrhage is an uncommon pathology in the general population, with a worldwide incidence of 9 per 100,000 people/year, but with a non-negligible risk of sequelae in terms of impairments, activity limitations and participation restrictions of around 30%. Mortality remains high at 40%, despite increasingly specialized care.

In addition, there are a number of objective, rapid assessment scores for autonomy and impairments, notably the modified Rankin score, which is not specific to subarachnoid hemorrhage, but which enables the study of patients' perceived quality of life. Certain factors predictive of bad patient outcome are known in the literature, but have been little studied in the population of Martinique.

02

Conditions studied

  • Subarachnoid Hemorrhage of Aneurysmal Cause

Keywords

  • SAH (Subarachnoid Hemorrhage)
  • Ruptured intracranial aneurysm
  • Modified Rankin score
  • Mortality
  • Patient autonomy
  • Patient dependence
03

In context

Subarachnoid Hemorrhage

510 studies on the registry are indexed under Subarachnoid Hemorrhage; 128 are open to participants now.

This study's planned enrollment of 122 is close to the median of 120 across 226 observational studies indexed under Subarachnoid Hemorrhage.

Browse Subarachnoid Hemorrhage studies →

Lead sponsor

University Hospital Center of Martinique is the lead sponsor of 79 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients hospitalized in Martinique for subarachnoid hemorrhage of aneurysmal origin

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (≥18 years) patients,
  • Admitted to University Hospital of Martinique with subarachnoid hemorrhage of aneurysmal origin between 01/01/2013 and 31/12/2021,
  • Informed patient/next-of-kin/treating physician consent for research participation.

Exclusion criteria

Exclusion Criteria:

  • Other causes of subarachnoid hemorrhage of non-aneurysmal origin (traumatic, arteriovenous malformation, cerebral tumor, cerebral thrombophlebitis).
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
122 participants (estimated)
Patient registry
No

Groups and cohorts

  • SAH of aneurysmal origin in hospitalized patients in Martinique between 2013 and 2021

    Other: Usual patient care for patients hospitalized for subarachnoid hemorrhage of aneurysmal origin

Interventions

  • OtherUsual patient care for patients hospitalized for subarachnoid hemorrhage of aneurysmal origin

    During hospitalization (2013-2021), patients were managed after multidisciplinary consultation in accordance with national recommendations between resuscitators, neurosurgeons and neuroradiologists, depending on the severity of the initial management and the patient's comorbidities, either by interventional radiology, neurosurgery or medical treatment.

06

What researchers measure

Primary outcomes

  1. Evaluate mortality in patients hospitalized for subarachnoid hemorrhage of aneurysmal origin over a 9-year period (2013-2021) in Martinique.

    Mortality of subarachnoid hemorrhage of aneurysmal origin.

    Time frame: 6 months

Secondary outcomes

  1. Evaluate the clinical outcome of these patients.

    Patient's clinical outcome (mortality, impairment of patient autonomy, impairment of patient's level of dependece), assessed with the modified Rankin score at discharge and at a distance from hospitalization (minimum delay: 2.5 years).

    Time frame: 6 months

  2. Analyze the factors associated with a significant impairment of autonomy and/or dependence.

    Predictive factors associated with significant impairment of patient autonomy and/or dependence (modified Rankin score = 4 or 5): age, degree of consciousness at the time of treatment (WFNS score), amount of blood in the meningeal spaces (Fisher score), aneurysm size

    Time frame: 6 months

  3. Analyze the factors associated with death.

    Predictive factors associated with death (modified Rankin score = 6): age, degree of consciousness at the time of treatment (WFNS score), amount of blood in the meningeal spaces (Fisher score), aneurysm size.

    Time frame: 6 months

  4. Analyze the factors associated with a poor prognosis (death AND/OR significant impairment of autonomy/dependence).

    Predictive factors associated with a poor prognosis (modified Rankin score ≥ 4: death AND/OR impaired patient autonomy and/or dependence): age, degree of consciousness at the time of treatment (WFNS score), amount of blood in the meningeal spaces (Fisher score), aneurysm size.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06525012
Lead sponsor
University Hospital Center of Martinique
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Jul 19, 2024
Primary completion
Dec 31, 2024
Completion
Apr 1, 2025 (estimated)
Last update
Mar 31, 2025

Study contacts

Marie SABIA, PhD
Contact
marie.sabia@chu-martinique.fr
0596551054 ext. +596
Pauline PICHOIS
Contact
paulinep13@live.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion